Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pharmion licenses cancer candidate from MethylGene

Executive Summary

Pharmion (oncology and hematology therapeutics) has licensed from fellow cancer drug developer MethylGene research, development, and commercialization rights to histone deacetylase (HDAC) inhibitors, including MethylGene's Phase I MGCD0103 for solid tumors and blood cancers as well as the company's pipeline of second-generation HDAC inhibitors for cancer indications.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies